Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346561 | 0.76 | SIGMAR1 (0.55) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL29204433 | 0.71 | SIGMAR1 (0.60) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL6346542 | 0.70 | SIGMAR1 (0.55) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL3403510 | 0.70 | SIGMAR1 (0.55) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL1588897 | 0.70 | SIGMAR1 (0.55) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL30484433 | 0.70 | SIGMAR1 (0.55) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL14154427 | 0.69 | SIGMAR1 (0.65) | SIGMAR1TMEM97CCR2 | |
| SCHEMBL30623485 | 0.69 | SIGMAR1 (0.69) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL25447581 | 0.68 | SIGMAR1 (0.49) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL29531860 | 0.68 | SIGMAR1 (0.52) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261327-A1 | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation | MERCK & CO., INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261327-A1 | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation | BDKRB1, BDKRB2, LTB4R2 | SIGMAR1 1107/4885TMEM97 2334/4885OPRM1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.